Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
New Novartis¹: Our focused strategy
Focusing on high-value innovative medicines that alleviate society's greatest disease
burdens through technology leadership in R&D and novel access approaches
Our focus
5 core Therapeutic Areas²
Cardiovascular, Immunology,
Neuroscience, Solid Tumors, Hematology
2 + 3 technology platforms
Chemistry, Biotherapeutics
XRNA, Radioligand, Gene & Cell Therapy
4 priority geographies
US, China, Germany, Japan
STRATEGY
Our priorities
Accelerate growth
Deliver returns
Strengthen foundations
Deliver high-value
medicines (including
launch excellence)
Embed operational
excellence
Unleash the power
of our people
Scale data science
and technology
Build trust with society
1. New Novartis here and in the rest of the presentation refers to Novartis assuming planned Sandoz spin-off. Subject to final Novartis AG BoD and shareholder approval (EGM).
2. Other TAs opportunistically.
5 Investor Relations | Q4 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation